Wegovy vs. Orlistat
Wegovy and Orlistat differ vastly in mechanism and effectiveness. Wegovy is a GLP-1 receptor agonist achieving an average 15% bodyweight loss by reducing appetite and slowing gastric emptying. Orlistat, a lipase inhibitor, prevents fat absorption and typically leads to modest weight loss. Wegovy lacks off-label uses, while Orlistat is sometimes used in overweight individuals without obesity. Side effects differ: Wegovy may cause nausea, while Orlistat is associated with gastrointestinal issues like oily stools. Wegovy is significantly costlier at $1,375/month compared to Orlistat’s $100. Neither drug currently faces shortages.
Slows gastric emptying, reduces appetite, and enhances feelings of fullness, leading to lower calorie intake. It also stimulates insulin release and reduces glucagon secretion, improving blood sugar control.
Common Side Effects
Nausea, vomiting, diarrhea, constipation, abdominal pain, headache, and fatigue.
Serious Potential Side Effects
Pancreatitis, gallbladder issues, kidney problems, and increased heart rate, thyroid cancer, anaphylaxis (or serious allergic reactions)
Blocks the breakdown and absorption of dietary fat in the intestines. Unabsorbed fat is excreted in the stool, reducing calorie intake and promoting weight loss.
Common Side Effects
Oily or fatty stools, frequent bowel movements, flatulence with discharge, and abdominal discomfort.
Serious Potential Side Effects
Rare liver damage and malabsorption of fat-soluble vitamins (A, D, E, K), kidney problems, and severe allergic reactions